Metastatic Pancreatic Cancer - Pipeline Review, H2 2016

Date: September 21, 2016
Pages: 416
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M2987F8F9C2EN
Leaflet:

Download PDF Leaflet

Metastatic Pancreatic Cancer - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Metastatic Pancreatic Cancer - Pipeline Review, H2 2016’, provides an overview of the Metastatic Pancreatic Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Pancreatic Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Pancreatic Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape of Metastatic Pancreatic Cancer
  • The report reviews pipeline therapeutics for Metastatic Pancreatic Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Metastatic Pancreatic Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Metastatic Pancreatic Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Metastatic Pancreatic Cancer
Reasons to buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Metastatic Pancreatic Cancer
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Metastatic Pancreatic Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope:
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Metastatic Pancreatic Cancer Overview
Therapeutics Development
Pipeline Products for Metastatic Pancreatic Cancer - Overview
Pipeline Products for Metastatic Pancreatic Cancer - Comparative Analysis
Metastatic Pancreatic Cancer - Therapeutics under Development by Companies
Metastatic Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes
Metastatic Pancreatic Cancer - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Metastatic Pancreatic Cancer - Products under Development by Companies
Metastatic Pancreatic Cancer - Products under Investigation by Universities/Institutes
Metastatic Pancreatic Cancer - Companies Involved in Therapeutics Development
AbbVie Inc
Aduro BioTech, Inc.
ArQule, Inc.
Array BioPharma Inc.
AstraZeneca Plc
Axcentua Pharmaceuticals AB
Berg LLC
BioLineRx, Ltd.
Bionomics Limited
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Celgene Corporation
Clovis Oncology, Inc.
Cornerstone Pharmaceuticals, Inc.
CrystalGenomics, Inc.
CTI BioPharma Corp.
CytRx Corporation
Daiichi Sankyo Company, Limited
Eleison Pharmaceuticals LLC
Eli Lilly and Company
Ensol Biosciences Inc.
Erytech Pharma SA
F. Hoffmann-La Roche Ltd.
Fountain Biopharma Inc.
Gilead Sciences, Inc.
GlaxoSmithKline Plc
Immodulon Therapeutics Ltd.
Incyte Corporation
MabVax Therapeutics Holdings, Inc.
Merck & Co., Inc.
Merrimack Pharmaceuticals, Inc.
NanoCarrier Co., Ltd.
NantKwest, Inc.
Natco Pharma Limited
NewLink Genetics Corporation
Novartis AG
Oncolytics Biotech Inc.
Oncovir, Inc.
Oryx GmbH & Co. KG
Pfizer Inc.
Pharmacyclics, Inc.
Phoenix Biotechnology, Inc.
Precision Biologics, Inc.
Rexahn Pharmaceuticals, Inc.
Silence Therapeutics Plc
Targovax ASA
Tiltan Pharma Ltd.
Tocagen Inc.
Zeria Pharmaceutical Co., Ltd.
Metastatic Pancreatic Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(curcumin + gemcitabine hydrochloride + paclitaxel) - Drug Profile
5B1-ADC - DRUG PROFILE
acalabrutinib - Drug Profile
aldoxorubicin hydrochloride - Drug Profile
alpelisib - Drug Profile
ARQ-761 - Drug Profile
asparaginase - Drug Profile
atezolizumab - Drug Profile
Atu-027 - Drug Profile
avasimibe - Drug Profile
AXP-10711 - Drug Profile
BI-853520 - Drug Profile
binimetinib - Drug Profile
BL-8040 - Drug Profile
BNC-101 - Drug Profile
Cellular Immunotherapy for Oncology - Drug Profile
Cellular Immunotherapy for Oncology - Drug Profile
Cellular Immunotherapy to Target GM-CSFR for Pancreatic Cancer - Drug Profile
ceritinib - Drug Profile
CG-200745 - Drug Profile
Charis-1000 - Drug Profile
CIM-1 - Drug Profile
cisplatin - Drug Profile
CPI-613 - Drug Profile
dacomitinib - Drug Profile
ensituximab - Drug Profile
FB-704A - Drug Profile
flucytosine ER + vocimagene amiretrorepvec - Drug Profile
galunisertib - Drug Profile
glufosfamide - Drug Profile
GS-5745 - Drug Profile
GSK-2256098 - Drug Profile
haNK Program - Drug Profile
HuMab-5B1 - Drug Profile
ibrutinib - Drug Profile
IMM-101 - Drug Profile
INCB-52793 - Drug Profile
indoximod - Drug Profile
irinotecan hydrochloride - Drug Profile
istiratumab - Drug Profile
lapatinib ditosylate - Drug Profile
LCL-161 - Drug Profile
MesoCART - Drug Profile
MK-2206 - Drug Profile
MK-2206 + selumetinib sulfate - Drug Profile
Monoclonal Antibody Conjugate to Target Mesothelin for Oncology - Drug Profile
MVT-1075 - Drug Profile
napabucasin - Drug Profile
nimotuzumab - Drug Profile
NRCAN-019 - Drug Profile
olaparib - Drug Profile
paclitaxel albumin bound - Drug Profile
palbociclib - Drug Profile
Parvoryx - Drug Profile
PBI-05204 - Drug Profile
PCI-27483 - Drug Profile
pelareorep - Drug Profile
PLX-7486 - Drug Profile
Poly-ICLC - Drug Profile
PRI-724 - Drug Profile
RG-7876 - Drug Profile
ribociclib succinate - Drug Profile
rottlerin - Drug Profile
rucaparib camsylate - Drug Profile
RX-0201 - Drug Profile
SGT-53 - Drug Profile
Small Molecules to Inhibit Lysyl Oxidase for Metastatic Pancreatic Cancer - Drug Profile
sonidegib phosphate - Drug Profile
TG-01 - Drug Profile
TL-118 - Drug Profile
tosedostat - Drug Profile
trametinib dimethyl sulfoxide - Drug Profile
ubidecarenone - Drug Profile
ulixertinib - Drug Profile
ulocuplumab - Drug Profile
Vaccine for Oncology - Drug Profile
veliparib - Drug Profile
Z-360 - Drug Profile
Metastatic Pancreatic Cancer - Dormant Projects
Metastatic Pancreatic Cancer - Discontinued Products
Metastatic Pancreatic Cancer - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 410

LIST OF TABLES

Number of Products under Development for Metastatic Pancreatic Cancer, H2 2016
Number of Products under Development for Metastatic Pancreatic Cancer - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Investigation by Universities/Institutes, H2 2016
Metastatic Pancreatic Cancer - Pipeline by AbbVie Inc, H2 2016
Metastatic Pancreatic Cancer - Pipeline by Aduro BioTech, Inc., H2 2016
Metastatic Pancreatic Cancer - Pipeline by ArQule, Inc., H2 2016
Metastatic Pancreatic Cancer - Pipeline by Array BioPharma Inc., H2 2016
Metastatic Pancreatic Cancer - Pipeline by AstraZeneca Plc, H2 2016
Metastatic Pancreatic Cancer - Pipeline by Axcentua Pharmaceuticals AB, H2 2016
Metastatic Pancreatic Cancer - Pipeline by Berg LLC, H2 2016
Metastatic Pancreatic Cancer - Pipeline by BioLineRx, Ltd., H2 2016
Metastatic Pancreatic Cancer - Pipeline by Bionomics Limited, H2 2016
Metastatic Pancreatic Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Metastatic Pancreatic Cancer - Pipeline by Boston Biomedical, Inc., H2 2016
Metastatic Pancreatic Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016
Metastatic Pancreatic Cancer - Pipeline by Celgene Corporation, H2 2016
Metastatic Pancreatic Cancer - Pipeline by Clovis Oncology, Inc., H2 2016
Metastatic Pancreatic Cancer - Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2016
Metastatic Pancreatic Cancer - Pipeline by CrystalGenomics, Inc., H2 2016
Metastatic Pancreatic Cancer - Pipeline by CTI BioPharma Corp., H2 2016
Metastatic Pancreatic Cancer - Pipeline by CytRx Corporation, H2 2016
Metastatic Pancreatic Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
Metastatic Pancreatic Cancer - Pipeline by Eleison Pharmaceuticals LLC, H2 2016
Metastatic Pancreatic Cancer - Pipeline by Eli Lilly and Company, H2 2016
Metastatic Pancreatic Cancer - Pipeline by Ensol Biosciences Inc., H2 2016
Metastatic Pancreatic Cancer - Pipeline by Erytech Pharma SA, H2 2016
Metastatic Pancreatic Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Metastatic Pancreatic Cancer - Pipeline by Fountain Biopharma Inc., H2 2016
Metastatic Pancreatic Cancer - Pipeline by Gilead Sciences, Inc., H2 2016
Metastatic Pancreatic Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016
Metastatic Pancreatic Cancer - Pipeline by Immodulon Therapeutics Ltd., H2 2016
Metastatic Pancreatic Cancer - Pipeline by Incyte Corporation, H2 2016
Metastatic Pancreatic Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H2 2016
Metastatic Pancreatic Cancer - Pipeline by Merck & Co., Inc., H2 2016
Metastatic Pancreatic Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016
Metastatic Pancreatic Cancer - Pipeline by NanoCarrier Co., Ltd., H2 2016
Metastatic Pancreatic Cancer - Pipeline by NantKwest, Inc., H2 2016
Metastatic Pancreatic Cancer - Pipeline by Natco Pharma Limited, H2 2016
Metastatic Pancreatic Cancer - Pipeline by NewLink Genetics Corporation, H2 2016
Metastatic Pancreatic Cancer - Pipeline by Novartis AG, H2 2016
Metastatic Pancreatic Cancer - Pipeline by Oncolytics Biotech Inc., H2 2016
Metastatic Pancreatic Cancer - Pipeline by Oncovir, Inc., H2 2016
Metastatic Pancreatic Cancer - Pipeline by Oryx GmbH & Co. KG, H2 2016
Metastatic Pancreatic Cancer - Pipeline by Pfizer Inc., H2 2016
Metastatic Pancreatic Cancer - Pipeline by Pharmacyclics, Inc., H2 2016
Metastatic Pancreatic Cancer - Pipeline by Phoenix Biotechnology, Inc., H2 2016
Metastatic Pancreatic Cancer - Pipeline by Precision Biologics, Inc., H2 2016
Metastatic Pancreatic Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2016
Metastatic Pancreatic Cancer - Pipeline by Silence Therapeutics Plc, H2 2016
Metastatic Pancreatic Cancer - Pipeline by Targovax ASA, H2 2016
Metastatic Pancreatic Cancer - Pipeline by Tiltan Pharma Ltd., H2 2016
Metastatic Pancreatic Cancer - Pipeline by Tocagen Inc., H2 2016
Metastatic Pancreatic Cancer - Pipeline by Zeria Pharmaceutical Co., Ltd., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Metastatic Pancreatic Cancer - Dormant Projects, H2 2016
Metastatic Pancreatic Cancer - Dormant Projects (Contd..1), H2 2016
Metastatic Pancreatic Cancer - Dormant Projects (Contd..2), H2 2016
Metastatic Pancreatic Cancer - Dormant Projects (Contd..3), H2 2016
Metastatic Pancreatic Cancer - Dormant Projects (Contd..4), H2 2016
Metastatic Pancreatic Cancer - Discontinued Products, H2 2016
Metastatic Pancreatic Cancer - Discontinued Products (Contd..1), H2 2016
Metastatic Pancreatic Cancer - Discontinued Products (Contd..2), H2 2016 402

LIST OF FIGURES

Number of Products under Development for Metastatic Pancreatic Cancer, H2 2016
Number of Products under Development for Metastatic Pancreatic Cancer - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Pancreatic Cancer - Pipeline Review, H2 2015 US$ 2,125.00 Dec, 2015 · 1769 pages
Metastatic Breast Cancer - Pipeline Review, H2 2015 US$ 1,700.00 Dec, 2015 · 966 pages
Metastatic Liver Cancer - Pipeline Review, H2 2015 US$ 1,600.00 Oct, 2015 · 58 pages

Ask Your Question

Metastatic Pancreatic Cancer - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: